3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
CNS
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
8
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
pembrolizumab
3
Everolimus
3
cabozantinib
2
X-Rays
2
repotrectinib
1
peposertib
1
pazopanib
1
olaparib
1
lenvatinib
1
fludarabine
1
entrectinib
1
belinostat
1
aldesleukin
1
Watchful Waiting
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Sunitinib
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
Photons
1
Phantoms, Imaging
1
PT-100 dipeptide
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
entrectinib
×
NET
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA